Scholarlink

<p>Chemoresistance in esophageal cancer (EC) continues to impose formidable clinical challenges, driving disease recurrence and adverse outcomes. While vesicle-associated membrane protein 7 (VAMP7), a SNARE family regulator, has emerged as an oncogenic participant in tumor evolution, its mechanistic role in EC chemoresistance remains uncharted. Clinico-pathological analyses reveal pronounced VAMP7 overexpression in EC specimens, correlating with unfavorable prognosis, metastatic dissemination, advanced tumor staging, and cisplatin-refractory phenotypes. Functional interrogation demonstrates that VAMP7 silencing attenuates malignant hallmarks-proliferation, migratory capacity, and epithelial-mesenchymal transition (EMT)-while potentiating apoptotic cascades. Mechanistically, VAMP7 exhibits robust positive correlation with ferroptosis regulators GPX4 and NRF2, establishing its role as a ferroptosis checkpoint inhibitor that sustains cisplatin resistance. Combinatorial VAMP7 depletion and cisplatin treatment synergistically diminished neoplastic viability through dual mechanisms: amplification of ferroptosis biomarkers (lipid peroxidation, iron dysregulation) and induction of mitochondrial ultrastructural derangements. Conversely, ectopic VAMP7 expression in resistant clones upregulated GPX4/NRF2 axis activity and reinstated chemotolerance. Therapeutically, co-administration of ferroptosis agonists (RSL3/Erastin) with cisplatin abrogated VAMP7-mediated resistance, evidenced by suppressed xenograft growth and amplified mitochondrial pathology in preclinical models. This work identifies VAMP7 as a novel ferroptosis-chemoresistance nexus in EC, offering a translational framework for overcoming cisplatin refractoriness through coordinated inhibition of VAMP7 signaling and ferroptosis potentiation.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

VAMP7 governs ferroptosis suppression and cisplatin resistance in esophageal cancer: a dual-targeting therapeutic paradigm

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月3日

查看全文
  • Jialiang Zhu,
  • Minghua Xie,
  • Lei Dai,
  • Zhiming Yang,
  • Wenbo Xue,
  • Zhibin Jiang,
  • Jingyue Zhou

摘要

Chemoresistance in esophageal cancer (EC) continues to impose formidable clinical challenges, driving disease recurrence and adverse outcomes. While vesicle-associated membrane protein 7 (VAMP7), a SNARE family regulator, has emerged as an oncogenic participant in tumor evolution, its mechanistic role in EC chemoresistance remains uncharted. Clinico-pathological analyses reveal pronounced VAMP7 overexpression in EC specimens, correlating with unfavorable prognosis, metastatic dissemination, advanced tumor staging, and cisplatin-refractory phenotypes. Functional interrogation demonstrates that VAMP7 silencing attenuates malignant hallmarks-proliferation, migratory capacity, and epithelial-mesenchymal transition (EMT)-while potentiating apoptotic cascades. Mechanistically, VAMP7 exhibits robust positive correlation with ferroptosis regulators GPX4 and NRF2, establishing its role as a ferroptosis checkpoint inhibitor that sustains cisplatin resistance. Combinatorial VAMP7 depletion and cisplatin treatment synergistically diminished neoplastic viability through dual mechanisms: amplification of ferroptosis biomarkers (lipid peroxidation, iron dysregulation) and induction of mitochondrial ultrastructural derangements. Conversely, ectopic VAMP7 expression in resistant clones upregulated GPX4/NRF2 axis activity and reinstated chemotolerance. Therapeutically, co-administration of ferroptosis agonists (RSL3/Erastin) with cisplatin abrogated VAMP7-mediated resistance, evidenced by suppressed xenograft growth and amplified mitochondrial pathology in preclinical models. This work identifies VAMP7 as a novel ferroptosis-chemoresistance nexus in EC, offering a translational framework for overcoming cisplatin refractoriness through coordinated inhibition of VAMP7 signaling and ferroptosis potentiation.

Graphical abstract